intetumumab
polyantigenic
immunorepressive
bivatuzumab
-zumab
agonistic monoclonal antibody
immunodomination
cergutuzumab
heteroclitic
histoantigen
amlitelimab
antinucleosome
neoantigen
ozogamicin
polyantibody
multiantigen
pathoantigen
antihuman
immunochemistry
pidilizumab
brolucizumab
pozelimab
toripalimab
immunosorbent
olaratumab
radioimmunology
dinutuximab
solitomab
zenocutuzumab
polyvalent
retifanlimab
ziltivekimab
gevokizumab
ravulizumab
sintilimab
tislelizumab
vanucizumab
abagovomab
sasanlimab
immunohistopathologic
antimouse
cibisatamab
immunoprobe
glembatumumab
heterophile